Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$15.35
-0.01000-0.07%
At close: -
$15.35
0.000.00%
After Hours: 4:42 PM EDT
Comments
Loading...
Mineralys Therapeutics Analyst Ratings and Price Targets | NASDAQ:MLYS | Benzinga
Mineralys Therapeutics Inc has a consensus price target of $35.67 based on the ratings of 8 analysts. The high is $45 issued by Stifel on March 7, 2023. The low is $24 issued by Goldman Sachs on February 13, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on May 13, 2025, April 2, 2025, and March 10, 2025, respectively. With an average price target of $38 between HC Wainwright & Co., there's an implied 147.56% upside for Mineralys Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Goldman Sachs
Credit Suisse
Wells Fargo
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Mineralys Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2025 | Buy Now | 173.62% | HC Wainwright & Co. | Matthew Caufield36% | $42 → $42 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2025 | Buy Now | 173.62% | HC Wainwright & Co. | Matthew Caufield36% | $30 → $42 | Maintains | Buy | Get Alert |
| 03/10/2025 | Buy Now | 95.44% | HC Wainwright & Co. | Matthew Caufield36% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 02/24/2025 | Buy Now | — | Guggenheim | Seamus Fernandez57% | — | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | 56.35% | Goldman Sachs | Richard Law43% | $28 → $24 | Maintains | Buy | Get Alert |
| 02/13/2025 | Buy Now | 95.44% | HC Wainwright & Co. | Matthew Caufield36% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 11/12/2024 | Buy Now | 95.44% | HC Wainwright & Co. | Matthew Caufield36% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 95.44% | HC Wainwright & Co. | Matthew Caufield36% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2024 | Buy Now | 95.44% | HC Wainwright & Co. | Matthew Caufield36% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2024 | Buy Now | 95.44% | HC Wainwright & Co. | Matthew Caufield36% | → $30 | Initiates | → Buy | Get Alert |
| 04/02/2024 | Buy Now | 95.44% | Goldman Sachs | Richard Law43% | → $30 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | 141.04% | Credit Suisse | Richard Law43% | $38 → $37 | Maintains | Outperform | Get Alert |
| 05/16/2023 | Buy Now | 147.56% | Credit Suisse | Richard Law43% | → $38 | Reiterates | Outperform → Outperform | Get Alert |
| 03/16/2023 | Buy Now | 147.56% | Credit Suisse | Richard Law43% | $40 → $38 | Maintains | Outperform | Get Alert |
| 03/07/2023 | Buy Now | — | Evercore ISI Group | Umer Raffat42% | — | Initiates | → Outperform | Get Alert |
| 03/07/2023 | Buy Now | 75.9% | Wells Fargo | Mohit Bansal66% | → $27 | Initiates | → Overweight | Get Alert |
| 03/07/2023 | Buy Now | 160.59% | Credit Suisse | Richard Law43% | → $40 | Initiates | → Outperform | Get Alert |
| 03/07/2023 | Buy Now | 108.47% | Guggenheim | Seamus Fernandez57% | → $32 | Initiates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 154.07% | B of A Securities | Greg Harrison48% | → $39 | Initiates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 193.16% | Stifel | Annabel Samimy66% | → $45 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Mineralys Therapeutics (MLYS) stock?
The latest price target for Mineralys Therapeutics (NASDAQ:MLYS) was reported by HC Wainwright & Co. on May 13, 2025. The analyst firm set a price target for $42.00 expecting MLYS to rise to within 12 months (a possible 173.62% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Mineralys Therapeutics (MLYS)?
The latest analyst rating for Mineralys Therapeutics (NASDAQ:MLYS) was provided by HC Wainwright & Co., and Mineralys Therapeutics reiterated their buy rating.
When was the last upgrade for Mineralys Therapeutics (MLYS)?
There is no last upgrade for Mineralys Therapeutics
When was the last downgrade for Mineralys Therapeutics (MLYS)?
There is no last downgrade for Mineralys Therapeutics.
When is the next analyst rating going to be posted or updated for Mineralys Therapeutics (MLYS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mineralys Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mineralys Therapeutics was filed on May 13, 2025 so you should expect the next rating to be made available sometime around May 13, 2026.
Is the Analyst Rating Mineralys Therapeutics (MLYS) correct?
While ratings are subjective and will change, the latest Mineralys Therapeutics (MLYS) rating was a reiterated with a price target of $42.00 to $42.00. The current price Mineralys Therapeutics (MLYS) is trading at is $15.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
